Cargando…

Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice

Cisplatin is used to combat solid tumors. However, patients treated with cisplatin often develop cognitive impairments, sensorimotor deficits, and peripheral neuropathy. There is no FDA-approved treatment for these neurotoxicities. We investigated the capacity of a highly selective A(3) adenosine re...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Anand Kumar, Mahalingam, Rajasekaran, Squillace, Silvia, Jacobson, Kenneth A., Tosh, Dilip K., Dharmaraj, Shruti, Farr, Susan A., Kavelaars, Annemieke, Salvemini, Daniela, Heijnen, Cobi J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800287/
https://www.ncbi.nlm.nih.gov/pubmed/35093182
http://dx.doi.org/10.1186/s40478-022-01315-w
_version_ 1784642227950059520
author Singh, Anand Kumar
Mahalingam, Rajasekaran
Squillace, Silvia
Jacobson, Kenneth A.
Tosh, Dilip K.
Dharmaraj, Shruti
Farr, Susan A.
Kavelaars, Annemieke
Salvemini, Daniela
Heijnen, Cobi J.
author_facet Singh, Anand Kumar
Mahalingam, Rajasekaran
Squillace, Silvia
Jacobson, Kenneth A.
Tosh, Dilip K.
Dharmaraj, Shruti
Farr, Susan A.
Kavelaars, Annemieke
Salvemini, Daniela
Heijnen, Cobi J.
author_sort Singh, Anand Kumar
collection PubMed
description Cisplatin is used to combat solid tumors. However, patients treated with cisplatin often develop cognitive impairments, sensorimotor deficits, and peripheral neuropathy. There is no FDA-approved treatment for these neurotoxicities. We investigated the capacity of a highly selective A(3) adenosine receptor (AR) subtype (A(3)AR) agonist, MRS5980, to prevent and reverse cisplatin-induced neurotoxicities. MRS5980 prevented cisplatin-induced cognitive impairment (decreased executive function and impaired spatial and working memory), sensorimotor deficits, and neuropathic pain (mechanical allodynia and spontaneous pain) in both sexes. At the structural level, MRS5980 prevented the cisplatin-induced reduction in markers of synaptic integrity. In-situ hybridization detected Adora3 mRNA in neurons, microglia, astrocytes and oligodendrocytes. RNAseq analysis identified 164 genes, including genes related to mitochondrial function, of which expression was changed by cisplatin and normalized by MRS5980. Consistently, MRS5980 prevented cisplatin-induced mitochondrial dysfunction and decreased signs of oxidative stress. Transcriptomic analysis showed that the A(3)AR agonist upregulates genes related to repair pathways including NOTCH1 signaling and chromatin modification in the cortex of cisplatin-treated mice. Importantly, A(3)AR agonist administration after completion of cisplatin treatment resolved cognitive impairment, neuropathy and sensorimotor deficits. Our results highlight the efficacy of a selective A(3)AR agonist to prevent and reverse cisplatin-induced neurotoxicities via preventing brain mitochondrial damage and activating repair pathways. An A(3)AR agonist is already in cancer, clinical trials and our results demonstrate management of neurotoxic side effects of chemotherapy as an additional therapeutic benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01315-w.
format Online
Article
Text
id pubmed-8800287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88002872022-02-02 Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice Singh, Anand Kumar Mahalingam, Rajasekaran Squillace, Silvia Jacobson, Kenneth A. Tosh, Dilip K. Dharmaraj, Shruti Farr, Susan A. Kavelaars, Annemieke Salvemini, Daniela Heijnen, Cobi J. Acta Neuropathol Commun Research Cisplatin is used to combat solid tumors. However, patients treated with cisplatin often develop cognitive impairments, sensorimotor deficits, and peripheral neuropathy. There is no FDA-approved treatment for these neurotoxicities. We investigated the capacity of a highly selective A(3) adenosine receptor (AR) subtype (A(3)AR) agonist, MRS5980, to prevent and reverse cisplatin-induced neurotoxicities. MRS5980 prevented cisplatin-induced cognitive impairment (decreased executive function and impaired spatial and working memory), sensorimotor deficits, and neuropathic pain (mechanical allodynia and spontaneous pain) in both sexes. At the structural level, MRS5980 prevented the cisplatin-induced reduction in markers of synaptic integrity. In-situ hybridization detected Adora3 mRNA in neurons, microglia, astrocytes and oligodendrocytes. RNAseq analysis identified 164 genes, including genes related to mitochondrial function, of which expression was changed by cisplatin and normalized by MRS5980. Consistently, MRS5980 prevented cisplatin-induced mitochondrial dysfunction and decreased signs of oxidative stress. Transcriptomic analysis showed that the A(3)AR agonist upregulates genes related to repair pathways including NOTCH1 signaling and chromatin modification in the cortex of cisplatin-treated mice. Importantly, A(3)AR agonist administration after completion of cisplatin treatment resolved cognitive impairment, neuropathy and sensorimotor deficits. Our results highlight the efficacy of a selective A(3)AR agonist to prevent and reverse cisplatin-induced neurotoxicities via preventing brain mitochondrial damage and activating repair pathways. An A(3)AR agonist is already in cancer, clinical trials and our results demonstrate management of neurotoxic side effects of chemotherapy as an additional therapeutic benefit. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01315-w. BioMed Central 2022-01-29 /pmc/articles/PMC8800287/ /pubmed/35093182 http://dx.doi.org/10.1186/s40478-022-01315-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Singh, Anand Kumar
Mahalingam, Rajasekaran
Squillace, Silvia
Jacobson, Kenneth A.
Tosh, Dilip K.
Dharmaraj, Shruti
Farr, Susan A.
Kavelaars, Annemieke
Salvemini, Daniela
Heijnen, Cobi J.
Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
title Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
title_full Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
title_fullStr Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
title_full_unstemmed Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
title_short Targeting the A(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
title_sort targeting the a(3) adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800287/
https://www.ncbi.nlm.nih.gov/pubmed/35093182
http://dx.doi.org/10.1186/s40478-022-01315-w
work_keys_str_mv AT singhanandkumar targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT mahalingamrajasekaran targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT squillacesilvia targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT jacobsonkennetha targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT toshdilipk targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT dharmarajshruti targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT farrsusana targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT kavelaarsannemieke targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT salveminidaniela targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice
AT heijnencobij targetingthea3adenosinereceptortopreventandreversechemotherapyinducedneurotoxicitiesinmice